Market Research Logo

Neutropenia - Pipeline Review, H2 2016

Neutropenia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Neutropenia - Pipeline Review, H2 2016’, provides an overview of the Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Neutropenia
    • The report reviews pipeline therapeutics for Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Neutropenia therapeutics and enlists all their major and minor projects
    • The report assesses Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Neutropenia
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Neutropenia
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Neutropenia Overview
    Therapeutics Development
    Pipeline Products for Neutropenia - Overview
    Neutropenia - Therapeutics under Development by Companies
    Neutropenia - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Neutropenia - Products under Development by Companies
    Neutropenia - Companies Involved in Therapeutics Development
    Apotex Inc.
    BeyondSpring Pharmaceuticals, Inc.
    Biogenomics Limited
    Cellerant Therapeutics, Inc.
    Cleveland BioLabs, Inc.
    Coherus BioSciences, Inc.
    Dr. Reddy's Laboratories Limited
    Eurofarma Laboratorios S.A.
    Ligand Pharmaceuticals, Inc.
    NAL Pharmaceuticals Ltd.
    Prolong Pharmaceuticals, LLC
    Richter Gedeon Nyrt.
    Sandoz International GmbH
    Therapeutic Proteins International, LLC
    Toko Pharmaceutical Industries Co., Ltd.
    USV Pvt Ltd
    Neutropenia - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    ACN-8337 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CBLB-612 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EC-18 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LG-7455 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim (recombinant) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    plinabulin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    romyelocel-L - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ST-7 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tamibarotene - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Neutropenia - Dormant Projects
    Neutropenia - Product Development Milestones
    Featured News & Press Releases
    Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case
    Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (pegfilgrastim) Patent Case
    Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study
    May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication
    Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets
    Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
    Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study
    Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701
    Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program
    Dec 08, 2015: EMA started the evaluation of Richter’s marketing authorisation application for biosimilar pegfilgrastim
    Dec 07, 2015: Phase III Data Shows Sandoz’ Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product
    Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
    Oct 01, 2015: Coherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study
    Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study
    Feb 17, 2015: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil)
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Neutropenia, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Neutropenia - Pipeline by Apotex Inc., H2 2016
    Neutropenia - Pipeline by BeyondSpring Pharmaceuticals, Inc., H2 2016
    Neutropenia - Pipeline by Biogenomics Limited, H2 2016
    Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016
    Neutropenia - Pipeline by Cleveland BioLabs, Inc., H2 2016
    Neutropenia - Pipeline by Coherus BioSciences, Inc., H2 2016
    Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
    Neutropenia - Pipeline by Eurofarma Laboratorios S.A., H2 2016
    Neutropenia - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
    Neutropenia - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
    Neutropenia - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016
    Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2016
    Neutropenia - Pipeline by Sandoz International GmbH, H2 2016
    Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H2 2016
    Neutropenia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2016
    Neutropenia - Pipeline by USV Pvt Ltd, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Neutropenia - Dormant Projects, H2 2016
    Neutropenia - Dormant Projects (Contd..1), H2 2016
    List of Figures
    Number of Products under Development for Neutropenia, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report